Leading Korean CRO Selected to Run Sinovac Phase 3 COVID-19 Vaccine Trial in Bangladesh

Leading Korean CRO Selected to Run Sinovac Phase 3 COVID-19 Vaccine Trial in Bangladesh

A leading Korean contract research organization (CRO) called LSK Global Pharma Services will conduct the Phase 3 clinical trial of Sinovac’s COVID-19 vaccine candidate in Bangladesh. Targeting approximately 4,200 frontline health workers at seven Dhaka-based hospitals, this important vaccine trial centers on the nation in Asia with the second-highest number of COVID-19 cases—as of this writing it's 317,528.


Just a week ago, Bangladesh authorities approved the late-stage clinical trial sponsored by China’s Sinovac Biotech Ltd in a bid to be at the top of the list for the vaccine, reported Reuters. Already state medical research authorities had signed off a month previous. Bangladesh has been considering Indian vaccines as well due to the severity of the epidemic.

Heavily Population Centers

Sinovac is signing up large, heavily populated nations for Phase 3 clinical trials as the number of coronavirus cases in China continues downward. Meanwhile, Sinovac signed up Indonesia (268m) and Brazil (210m) and, of course, now Bangladesh (161m).

Busy Trial Sites

The hospitals selected as trial sites in the nation’s most populated city, Dhak (21m inhabitants), are t...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee